Venus Medtech (Hangzhou) (HKG:2500) said it filed for EU regulatory approval to begin selling its Cardiovalve system in the region, according to a Hong Kong bourse filing Wednesday.
The product is designed to treat both mitral regurgitation and tricuspid regurgitation in the heart.